Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 531 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Botulinum toxin A Clear all
Not listed Phase 4 Interventional

BOTOX® at the Time of Prolapse Surgery for OAB

NCT04807920
View directory record Official record
Conditions
Urinary Bladder, Overactive, Pelvic Organ Prolapse
Interventions
OnabotulinumtoxinA 100 UNT, Injectable saline
Drug · Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 2 Interventional

Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

NCT05216250
View directory record Official record
Conditions
Upper Limb Essential Tremor (UL ET)
Interventions
BOTOX, Placebo for BOTOX
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
36
States / cities
Hoover, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

NCT01358695
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1207, Botulinum Toxin Type A
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 30, 2026, 7:22 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A

NCT01483209
View directory record Official record
Conditions
Ischemia, Vasopressor
Interventions
Injection of botulinum toxin A
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

NCT00288509
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

NCT00407030
View directory record Official record
Conditions
Cervical Dystonia
Interventions
incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Upper Facial Remodeling With Perlane-L and Dysport

NCT01354743
View directory record Official record
Conditions
Mild to Moderate Temporal Atrophy, Moderate to Severe Glabellar Rhytids, Moderate to Severe Periorbital Rhytids
Interventions
Dysport, Perlane L
Drug · Device
Lead sponsor
Beer, Kenneth R., M.D., PA
Individual
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

NCT04631588
View directory record Official record
Conditions
Facial Fine Lines
Interventions
Botox, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 30, 2026, 7:22 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer

NCT07796490
View directory record Official record
Conditions
Prostate Cancer
Interventions
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo
Drug · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Recruiting No phase listed Observational

Targeting Nociceptors in Hidradenitis Suppurativa

NCT05403710
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hyperhidrosis
Interventions
Botulinum toxin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260
View directory record Official record
Conditions
Glabellar Lines, Lateral Canthal Lines
Interventions
botulinum toxin neuromodulator
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Sep 30, 2026, 7:22 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines

NCT07756580
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, BOTOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Glendale, Arizona • Newport Beach, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.

NCT01753310
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 30, 2026, 7:22 AM EDT
Terminated Phase 4 Interventional Results available

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

NCT03078270
View directory record Official record
Conditions
Anxiety Disorder Social, Anxiety
Interventions
botulinum toxin A, Placebo
Drug · Other
Lead sponsor
Daniel Lieberman
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 30, 2026, 7:22 AM EDT
Terminated Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT02973269
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
daxibotulinumtoxin type A, Placebo
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 30, 2026, 7:22 AM EDT
Not listed Phase 3 Interventional

Intra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain

NCT00211718
View directory record Official record
Conditions
Arthritis, Shoulder Pain
Interventions
intra-articular botulinum toxin type a
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2005 · Synced Sep 30, 2026, 7:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Botulinum for Chronic Exertional Compartment Syndrome

NCT03339921
View directory record Official record
Conditions
Chronic Exertional Compartment Syndrome
Interventions
Botulinum toxin injections for chronic compartment syndrome, surgical fasciotomy for chronic compartment syndrome
Drug · Procedure
Lead sponsor
375th Medical Group, Scott Air Force Base
Federal
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scott Air Force Base, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 30, 2026, 7:22 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris

NCT04240535
View directory record Official record
Conditions
Aging
Interventions
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Drug
Lead sponsor
Amir Moradi MD, MBA
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 3 Interventional

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

NCT06399718
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Newport Beach, California • Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 30, 2026, 7:22 AM EDT
Completed No phase listed Observational Results available

A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines

NCT01749410
View directory record Official record
Conditions
Chronic Migraine, Headaches
Interventions
onabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Sep 30, 2026, 7:22 AM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 30, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines

NCT05152576
View directory record Official record
Conditions
Forehead Lines
Interventions
OnabotulinumtoxinA X, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Newport Beach, California • Mount Kisco, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 30, 2026, 7:22 AM EDT
Not listed Not applicable Interventional

The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder

NCT02315950
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botulinum toxin and cineMRI-UDS
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 30, 2026, 7:22 AM EDT